CJC-1295 DAC

CJC-1295 is a synthetic growth-hormone-releasing hormone analog studied for extended GH/IGF-1 signaling.

Research Library CJC-1295 DAC

CJC-1295 DAC

Growth Hormone / RecoveryPerformance / Body Composition

CJC-1295 DAC 5 mg Research Profile & Reconstitution Reference

Research StatusClinical research Evidence LevelHuman clinical study Related Peptides6
RESEARCH PROFILE

Explore the compound

IdentityFormulationsResearchReferences

Quick Facts

Alternate NamesCJC-1295
Molecular FormulaNot listed
Molecular Weight~3647 Da
Research ClassGrowth Hormone / Recovery, Performance / Body Composition
Research StatusClinical research
Evidence ClassificationHuman clinical study
Half-LifeNot established
Physical Formlyophilized

Mechanism of Action

CJC-1295 is a synthetic growth-hormone-releasing hormone analog studied for extended GH/IGF-1 signaling. Its mechanism stimulates the pituitary GH axis, supporting research around recovery, lean tissue, and body composition.

Mechanism of Action: stimulates the pituitary GH axis, supporting research around recovery, lean tissue, and body composition.

  • Supports growth-hormone axis signaling, including GH pulse or IGF-pathway research depending on compound [1].
  • Commonly discussed for recovery, sleep quality, lean-mass support, and body-composition goals tied to GH biology [1].
  • Associated with muscle, connective-tissue, and metabolic research endpoints in PubMed-indexed literature [1].
  • Official trial and NIH database searches document the broader clinical/research landscape for this axis [2][3].

Research Applications & Context

Community-reported protocol schedules.

Research Dosage Information

Reported research quantities and their source context. These are not recommendations, and source status varies.

Scroll the table horizontally to read every column. Select a row to inspect it in the calculator.

Community report 1 · Weeks 1-2: 150mcg Once daily. Weeks 1-2. Community report 1 · Weeks 3-12: 300mcg Once daily. Weeks 3-12. Community report 2 · Weeks 1-2: 100mcg. Weeks 1-2. Community report 2 · Weeks 3-12: 150mcg. Weeks 3-12. Community report 3 · Weeks 1-12: 2000mcg Once weekly. Weeks 1-12. Community report 4 · Weeks 1-2: 300mcg 2 times weekly. Weeks 1-2. Community report 4 · Weeks 3-4: 500mcg 2 times weekly. Weeks 3-4. Community report 4 · Weeks 5-6: 750mcg 2 times weekly. Weeks 5-6. Community report 4 · Weeks 7-12: 1000mcg 2 times weekly. Weeks 7-12. Community report 5 · Initiation: 500-1000 mcg Once weekly. Community report 5 · Therapeutic range: 1000 mcg Once weekly. Community report 5 · Elevated dose: 2000 mcg Once weekly. Community report 5 · Maximum studied: 240 mcg/kg Once weekly.

Research dosage rows for CJC-1295 DAC
PhaseReported AmountFrequencyDraw UnitsCycleNotesCalculator
Community report 1 · Weeks 1-2150mcgOnce dailySelect a vialWeeks 1-2Community-reported protocol.
Community report 1 · Weeks 3-12300mcgOnce dailySelect a vialWeeks 3-12Community-reported protocol.
Community report 2 · Weeks 1-2100mcgSelect a vialWeeks 1-2Community-reported protocol.
Community report 2 · Weeks 3-12150mcgSelect a vialWeeks 3-12Community-reported protocol.
Community report 3 · Weeks 1-122000mcgOnce weeklySelect a vialWeeks 1-12Community-reported protocol.
Community report 4 · Weeks 1-2300mcg2 times weeklySelect a vialWeeks 1-2Community-reported protocol.
Community report 4 · Weeks 3-4500mcg2 times weeklySelect a vialWeeks 3-4Community-reported protocol.
Community report 4 · Weeks 5-6750mcg2 times weeklySelect a vialWeeks 5-6Community-reported protocol.
Community report 4 · Weeks 7-121000mcg2 times weeklySelect a vialWeeks 7-12Community-reported protocol.
Community report 5 · Initiation500-1000 mcgOnce weeklySelect a vialCommunity-reported protocol.
Community report 5 · Therapeutic range1000 mcgOnce weeklySelect a vialCommunity-reported protocol.
Community report 5 · Elevated dose2000 mcgOnce weeklySelect a vialCommunity-reported protocol. Reported alternatives: 2000 mcg once weekly or 1 mg twice weekly.
Community report 5 · Maximum studied240 mcg/kgOnce weeklySelect a vialCommunity-reported protocol.

Dosing Protocol & Schedule

Community-reported research schedules, not clinically validated protocols. Select a reported scenario and duration to calculate mathematical quantities.

PeriodResearch DoseFrequencyTotal InjectionsTotal amountVolume per entryU-100 equivalent

Strength changes affect volume and supplies, not the underlying community-reported quantities. Figures exceeding the selected syringe capacity are flagged; they are not instructions for splitting administrations.

Plan a Regimen Schedule

Save the selected research protocol to your private calendar. Scheduled entries never create Dose Logs.

Reconstitution Calculator

Select the vial strength you are examining. The reference chart displays examples, not recommended preparation volumes or validated protocols.

Reconstitution Calculation

Choose a compound to see the vial variants in the catalog.
Quantity in vial
Reconstitution AgentEnter the measured final solution volume. Actual reconstitution agent added may differ due to displacement.
Desired DoseMathematical research draw quantity; not a recommended dose.
Calculated equivalent
—units
Draw Amount (mg / mcg)
—
Draws per vial
—
Concentration
—
Draw Volume
—
Syringe Capacity
—
Final Solution Volume
—

Theoretical only. Confirm actual concentrations and measurement uncertainty.

U-100 volume reference—
Magnified graduation view

Magnified reading follows the calculated volume.

—

Illustrative capacity-specific U-100 volume scale. Actual increments vary by instrument. Biological IU is a separate dimension.

Side-by-Side Research Comparison

Compare two independent configurations

Compare compatible research quantities, concentrations and U-100 volume equivalents. The values below are independent of the main calculator.

Configuration A

Enter values and compare.

Concentration
—
Draw Volume
—
U-100 equivalent
—

Configuration B

Enter values and compare.

Concentration
—
Draw Volume
—
U-100 equivalent
—

Mathematical comparison only, not a recommended dose or preferred configuration. Concentrations compare only when quantity dimensions are compatible.

Private calculation history

Private calculation history

Sign in to save research calculations to your private history.

Reconstitution Reference Chart

Hypothetical volume comparisons for the selected vial. No particular volume is endorsed, and vial capacity, solubility, excipients and product-specific instructions are not established by this table.

Example volumeCalculated concentrationCalculator
1 mL—
2 mL—
3 mL—
4 mL—
5 mL—

Choose a compatible dry vial to see reference concentrations.

Research-only mathematical comparisons; not instructions to compound, prepare, or administer peptides. Community-reported protocols are not clinically validated by inclusion here.

Supplies Needed — Estimate

Select a vial strength and an example reconstitution volume below. Counts use only the checked, computable rows above; they are not product-specific sterility, compatibility, or stability guidance.

Total Injections—
Minimum vials by mass—
Total Syringes—
Reconstitution agent—
10 mL reconstitution-agent bottles—
Alcohol Swabs (2 per entry)—
Total quantity—

Select a compatible vial and volume below to view quantities.

Educational and entertainment purposes only. Research use only; not for human or animal administration. Pad counts assume two per Total entry; syringe counts include additional containers where a single entry exceeds the selected syringe capacity. Vial totals assume full theoretical recovery and do not account for dead volume, spoilage, asepsis, expiration, potency, route, or beyond-use dating. These figures are not a recommended supplies list for an actual procedure.

Published References (0 identified)

A recorded identifier identifies a publication; it does not establish that its claims have been independently verified.

Research indexes & other source links

Searches, registries and unverified source records are discovery resources, not verified published studies.

  1. PubMed.gov biomedical literature: CJC-1295 DAC View source ↗ PubMed index/search · Source link recorded; claim verification separate
  2. ClinicalTrials.gov study registry: CJC-1295 DAC View source ↗ ClinicalTrials.gov registry/search · Source link recorded; claim verification separate
  3. NIH/NCBI all-databases search: CJC-1295 DAC View source ↗ NCBI database/search · Source link recorded; claim verification separate
  4. PubChem / NIH compound record search: CJC-1295 DAC View source ↗ PubChem database/search · Source link recorded; claim verification separate
Faye
Faye
Articles: 249

Related Peptides

Print / Save PDF